Clinical Trial Update: Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Ningetinib (CT053PTSA) plus Gefitinib in stage IIIB/IV non-small cell lung cancer with EGFR mutation and T790M negative (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• Ningetinib (Ningetinib)

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN